Exact, distribution free confidence intervals for late effects in censored matched pairs.
When comparing censored survival times for matched treated and control subjects, a late effect on survival is one that does not begin to appear until some time has passed. In a study of provider specialty in the treatment of ovarian cancer, a late divergence in the Kaplan-Meier survival curves hinted at superior survival among patients of gynecological oncologists, who employ chemotherapy less intensively, when compared to patients of medical oncologists, who employ chemotherapy more intensively; we ask whether this late divergence should be taken seriously. Specifically, we develop exact, permutation tests, and exact confidence intervals formed by inverting the tests, for late effects in matched pairs subject to random but heterogeneous censoring. Unlike other exact confidence intervals with censored data, the proposed intervals do not require knowledge of censoring times for patients who die. Exact distributions are consequences of two results about signs, signed ranks, and their conditional independence properties. One test, the late effects sign test, has the binomial distribution; the other, the late effects signed rank test, uses nonstandard ranks but nonetheless has the same exact distribution as Wilcoxon's signed rank test. A simulation shows that the late effects signed rank test has substantially more power to detect late effects than do conventional tests. The confidence statement provides information about both the timing and magnitude of late effects.
Daniel
Shoshana R
SR
Covance Periapproval Services Inc., Conshohocken, PA 19428, USA. shani314@yahoo.com
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001699:Biometry / Q000379:methods; D003198:Computer Simulation; D016001:Confidence Intervals; D018849:Controlled Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D016555:Matched-Pair Analysis; D015233:Models, Statistical; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016008:Statistical Distributions; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents